Nektar Restructures A Second Time, Focusing Squarely On Immunology

 
• By Joseph Haas

A year after reducing headcount by 70%, Nektar is trimming another 60% and looking to partner out cancer candidate NKTR-255 to focus on rezpeg for atopic dermatitis, with or without Lilly’s help.

severing ties and boycott concept
Nektar slashed headcount to push its cash runway to 2026

More from Strategy

More from Business